{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:56:57Z","timestamp":1791464217848,"version":"4.3.4"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ygyno.2019.09.020","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T08:21:50Z","timestamp":1570609310000},"page":"400-405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study"],"prefix":"10.1016","volume":"155","author":[{"given":"C.","family":"Marchetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Scaletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pietragalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Arcieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ergasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Palluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2019.09.020_bib1","first-page":"7","article-title":"Cancer statistics","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.ygyno.2019.09.020_bib2","first-page":"421","article-title":"Treatment of recurrent epithelial ovarian cancer","volume":"5","author":"Pisano","year":"2009","journal-title":"Ther. Clin. Risk Manag."},{"issue":"22","key":"10.1016\/j.ygyno.2019.09.020_bib3","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ygyno.2019.09.020_bib4","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"issue":"10106","key":"10.1016\/j.ygyno.2019.09.020_bib5","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2019.09.020_bib6","article-title":"The role of secondary surgery in recurrent ovarian cancer","volume":"2012","author":"Lorusso","year":"2012","journal-title":"Int J Surg Oncol"},{"key":"10.1016\/j.ygyno.2019.09.020_bib7","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2017.35.15_suppl.5501","article-title":"Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20","volume":"35","author":"Du Bois","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.09.020_bib8","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2018.36.15_suppl.5501","volume":"36","author":"Coleman","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ygyno.2019.09.020_bib9","series-title":"International Gynecologic Cancer Society","article-title":"A\u00a0phase III randomized controlled trial of secondary cytoreductive surgery (SCS) followed by platinum-based chemotherapy (PC) platinum-sensitive, recurrent ovarian cancer (PSOC)\u2014surgical parameters","author":"Coleman","year":"2018"},{"issue":"3\u20134","key":"10.1016\/j.ygyno.2019.09.020_bib10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000159266","article-title":"A\u00a0treatment selection protocol for recurrent ovarian cancer patients: the role of FDGPET\/CT and staging laparoscopy","volume":"75","author":"Fagotti","year":"2008","journal-title":"Oncology"},{"issue":"2","key":"10.1016\/j.ygyno.2019.09.020_bib11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1245\/s10434-014-4011-0","article-title":"Positron emission tomography-laparoscopy based method in the prediction of complete cytoreduction in platinum-sensitive recurrent ovarian cancer","volume":"22","author":"Fanfani","year":"2015","journal-title":"Ann. Surg. Oncol."},{"issue":"14","key":"10.1016\/j.ygyno.2019.09.020_bib12","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.ejca.2006.03.025","article-title":"Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations","volume":"42","author":"Ferrandina","year":"2006","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2019.09.020_bib13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J.\u00a0Biomed. Inform."},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2019.09.020_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.5541","article-title":"Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): efficacy by surgical and tumor status in the Phase III SOLO1 trial","volume":"37","author":"Mathews","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"11\u201312","key":"10.1016\/j.ygyno.2019.09.020_bib15","first-page":"1727","article-title":"A\u00a0mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate","volume":"63","author":"Goldie","year":"1979","journal-title":"Cancer Treat Rep."},{"issue":"12","key":"10.1016\/j.ygyno.2019.09.020_bib16","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1245\/s10434-018-6700-6","article-title":"BRCA mutation status to personalize management of recurrent ovarian cancer: a multicenter study","volume":"25","author":"Marchetti","year":"2018","journal-title":"Ann. Surg. Oncol."},{"issue":"suppl_5","key":"10.1016\/j.ygyno.2019.09.020_bib17","first-page":"v330","article-title":"OReO\/ENGOT Ov-38: a Phase IIIb trial of olaparib maintenance retreatment in patients with epithelial ovarian cancer","volume":"28","author":"Pujade-Lauraine","year":"2017","journal-title":"Ann. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819315458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819315458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:47:01Z","timestamp":1758772021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819315458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0090825819315458"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.09.020","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}